A maternal link to Alzheimer's disease

People who have a mother with Alzheimer’s disease appear to be at higher risk for getting the disease than those individuals whose fathers are afflicted, according to a new study by NYU School of Medicine researchers.

The study is published in this week’s online edition of the Proceedings of the National Academy of Sciences. It is the first to compare brain metabolism among cognitively normal people who have a father, a mother, or no relatives with Alzheimer’s disease, and to show that only individuals with an affected mother have reduced brain metabolism in the same brain regions as Alzheimer’s patients.

Over the last two decades a number of studies have shown that people with the disease have significant reductions in brain energy metabolism in certain regions of the brain. In some recent research studies these reductions are evident in healthy people years before symptoms of dementia emerge.

The researchers wanted to evaluate people with a family history of Alzheimer’s because that is one of the biggest risk factors for the disease. Alzheimer’s affects more than 5 million Americans and is the most common form of senile dementia. People with an affected parent have a 4- to 10-fold higher risk compared to individuals with no family history. It isn’t known why people with a family history are more susceptible to the disease.

Likewise, it isn’t known why individuals with a history of the disease on their mother’s side are at increased risk for Alzheimer’s, and this observation must be replicated in larger studies before it could be of use in the clinic to perhaps identify people who may be more vulnerable to the disease, says Lisa Mosconi, Ph.D., Research Assistant Professor of Psychiatry at NYU School of Medicine, who led the new study. She speculates that genes that are maternally inherited might alter brain metabolism.

The new study involved 49 cognitively normal individuals, from 50 to 80 years old, who underwent a battery of neuropsychological and clinical tests, and PET (positron emission tomography) scans of their brains using a technique that labels glucose—the brain’s fuel—with a special chemical tracer. Sixteen subjects had a mother with the disease, and eight had a father with Alzheimer’s. The remaining subjects didn’t have a family history of the disease.

People with a maternal history of the disease had the largest reductions in glucose metabolism in several areas of the brain, including the medial temporal lobes and the posterior cingulate cortex, two brain regions involved with memory storage and retrieval. Brain energy metabolism was reduced by 25 percent in the posterior cingulate cortex in this group.

There weren’t any reductions in brain energy metabolism in the people without a family history and in those with a father who had the disease. The effects in glucose metabolism among subjects with a maternal history remained significant after accounting for possible risk factors for Alzheimer’s, including age, gender, education, Apolipoprotein E genotype, and subjective memory complaints.

“This is a preliminary study and the results have to be replicated,” says Dr. Mosconi. “What we need even more is to follow subjects over time until they develop clinical symptoms, and we really need to assess whether the metabolic reductions predict and correlate with disease progression,” she says.

“Energy metabolism hasn’t been a major focus of research in Alzheimer’s, so we hope that this study will stimulate further discussion on brain activity and disease risk, which could also be important for planning targeted therapeutic interventions,” says Dr. Mosconi.

“This is an intriguing finding,” says Mony de Leon, Ed.D., Professor of Psychiatry and Director of the Center for Brain Health at NYU School of Medicine. “It points to the need for more research to investigate the mechanisms of maternal transmission of this observed glucose metabolism deficit as well as to learn of any direct or indirect relationship to Alzheimer's disease," said Dr. de Leon.

Source: New York University Medical Center

Related stories:

Stem cell obstacles
"There are still a number of major hurdles in the path of stem cell research today that are preventing the routine application of the technology in regenerative medicine." So say UK scientists writing in a forthcoming issue of the International Journal of Biotechnology.
Fast-food linked to Alzheimer's: Swedish scientists
Mice that were fed a diet rich in fat, sugar and cholesterol for nine months developed a preliminary stage of the morbid irregularities that form in the brains of Alzheimer's patients. The study results, published in a doctoral thesis from the Swedish medical university Karolinska Institutet (KI), give some indications of how this difficult to treat disease might one day be preventable.
Scientists Seek to Block Progression of Alzheimer’s Disease with Novel Medication that Targets the Source
(PhysOrg.com) -- Researchers at the University of California, San Diego Shiley-Marcos Alzheimer’s Research Center (ADRC) are conducting studies on an experimental medication to block nerve damage and inflammation in the brain that can lead to progressive memory loss and behavioral changes in people with Alzheimer’s disease. While current Alzheimer’s disease therapies focus on improving symptoms, this study aims to attack the root of the disease progression. Nationwide, 400 volunteers with mild to moderate Alzheimer’s disease are needed to further test this new approach.
Alzheimer's disease breakthrough
CSIRO scientists have developed a new system to screen for compounds that can inhibit one of the processes that takes place during the progression of Alzheimer’s disease.
Breakthrough in cell-type analysis offers new ways to study development and disease
(PhysOrg.com) -- Like skilled assassins, many diseases seem to know exactly what types of cells to attack. While decimating one cadre of cells, diseases will inexplicably spare a seemingly identical group of neighbors. What makes cells vulnerable or not depends largely on the kinds and amounts of proteins they produce — their “translational profile,” in the lingo of molecular biology. For this reason, scientists have struggled to parse the subtle molecular differences among the hundreds of specialized cell types that are tangled together in tissues like the brain.
How the APOE gene can modify your risk for Alzheimer's disease
One of the hallmarks of the brain of an individual with Alzheimer disease is the accumulation of amyloid-beta peptide (A-beta), something that is believed to be toxic to many brain cells (specifically neurons) and to therefore contribute to the underlying cause of disease. Berislav Zlokovic and colleagues, at the University of Rochester Medical School, have now generated data in mice that mechanistically links a genetic risk factor for Alzheimer disease with accumulation of A-beta in the brain.
Brain imaging study supports the 'cognitive reserve' hypothesis
Individuals with higher education levels appear to score higher on cognitive tests despite having evidence of brain plaques associated with Alzheimer's disease, according to a report in the November issue of Archives of Neurology.
Pittsburgh Compound B finds Alzheimer's-associated plaques in symptom-free older adults
In the largest study of its kind, Pittsburgh Compound B, an imaging agent that could facilitate the early diagnosis of Alzheimer's disease, has been used to identify amyloid deposition in the brains of clinically older adults.

News discussion:

Medicine & Health news